PeeVee.TV
   

  ログイン

ホーム 新規ユーザー登録

新着動画一覧

01

サムネイル

(DGX) Stratify JCV gets de novo classification from FDA

Quest Diagnostics Inc - DGX - reported that the FDA has granted a de novo classification petition to its STRATIFY JCV Antibody ELISA testing service. STRATIFY JCV is the first blood test to be FDA market authorized for the qualitative detection of antibodies to the polyomavirus JC virus for stratifying risk for progressive multifocal leukoencephalopathy, an infrequent but serious brain infection, in patients with multiple sclerosis receiving TYSABRI (natalizumab), a highly effective therapy for relapsing forms of multiple sclerosis. Based on exclusive collaboration with Biogen Idec, the test is only available in the United States through Quest Diagnostics’ Focus Diagnostics lab. Quest Diagnostics provides diagnostic testing, information, and services in the United States and internationally. ********************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read the Full Disclaimer at http://www.crwenewswire.com/disclaimer)

投稿者:サイト名 karmastock
投稿日時:2012.1.22. 04:55
視聴回数:250回
お気に入り登録:0
カテゴリ: ニュース全般  
タグ: NYSE:DGX   DGX   Biogen   leukoencephalopathy   polyomavirus   STRATIFY-JCV  

01

   
videovar
iPeeVee iPeeVee

会社概要 |  ソリューション |  お問い合わせ |  スタッフ募集 |  利用規約 |  プライバシーポリシー

Copyright (C) 2006-2019 PeeVee Corporation. All rights reserved.